Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FLR001
MIFTS: 37

Filarial Elephantiasis

Categories: Rare diseases, Infectious diseases, Immune diseases, Eye diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Filarial Elephantiasis

About this section

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 12 53
Lymphatic Filariasis 12 76 53 59 55 3
Elephantiasis 53 73
Filariasis 53 73
Infection by Wuchereria Bancrofti 73
Wuchereria Bancrofti Infection 53
Bancroftian Filarial Chyluria 12
Malayi Tropical Eosinphilia 53
Bancroftian Elephantiasis 12
Elephantiasis of Eyelid 12
Elephantiasis, Filarial 44
Bancroftian Filariasis 53
Filarial Elephantiases 73
Wuchereriasis 53
Elephantitis 53

Characteristics:

Orphanet epidemiological data:

59
lymphatic filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Immune diseases Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12211
ICD10 33 B74.0
MeSH 44 D004605
Orphanet 59 ORPHA2035
ICD10 via Orphanet 34 B74.0 B74.1 B74.2
UMLS via Orphanet 74 C0013884
Sources

Summaries for Filarial Elephantiasis

About this section
NIH Rare Diseases : 53 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system, which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms. A small percentage of people develop lymphedema, which may affect the legs, arms, breasts, and genitalia; bacterial infections that cause hardening and thickening of the skin, called elephantiasis; hydrocele (swelling of the scrotum) in men; and pulmonary tropical eosinophilia syndrome. Treatment may include a yearly dose of medicine, called diethylcarbamazine (DEC); while this drug does not kill all of the adult worms, it prevents infected people from giving the disease to someone else.

MalaCards based summary : Filarial Elephantiasis, also known as lymphatic filariasis, is related to filariasis and loiasis, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10). The drugs Albendazole and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye.

Disease Ontology : 12 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

CDC : 3 Lymphatic filariasis, considered globally as a neglected tropical disease, is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body’s fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.

Wikipedia : 76 Lymphatic filariasis, also known as elephantiasis, is a human disease caused by parasitic worms known as... more...

Sources

Related Diseases for Filarial Elephantiasis

About this section

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 filariasis 12.6
2 loiasis 12.0
3 podoconiosis 11.6
4 lymphedema 11.6
5 dirofilariasis 11.4
6 elephantiasis 10.7
7 hydrocele 10.1

Graphical network of the top 20 diseases related to Filarial Elephantiasis:



Diseases related to Filarial Elephantiasis
Sources

Symptoms & Phenotypes for Filarial Elephantiasis

About this section

UMLS symptoms related to Filarial Elephantiasis:


chyluria
Sources

Drugs & Therapeutics for Filarial Elephantiasis

About this section

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54965-21-8 2082
2
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70288-86-7 6474909
3
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 90-89-1 3052
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 564-25-0 54671203
5
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 55268-74-1 4891
6
Azithromycin Approved Phase 4,Phase 2,Not Applicable 83905-01-5 55185 447043
7 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Lipoxygenase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Antimalarials Phase 4,Phase 3,Phase 2
15 Anticonvulsants Phase 4
16
Glycerol Approved, Investigational Phase 3 56-81-5 753
17
Petrolatum Approved, Investigational Phase 3 8009-03-8
18 Disinfectants Phase 3
19 Eusol Phase 3
20 Protective Agents Phase 3
21 Sodium hypochlorite Phase 3
22 Vitamins Phase 3
23 Milbemycin Phase 3,Phase 2
24
Dihydroartemisinin Approved, Investigational Phase 2 71939-50-9 6918483
25
Piperaquine Approved, Investigational Phase 2 4085-31-8 5079497
26
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
27 Artemisinine Phase 2
28 Artemisinins Phase 2
29 Anti-Asthmatic Agents Phase 2
30 Antibodies Phase 2
31 Antibodies, Monoclonal Phase 2
32 Immunoglobulins Phase 2
33 Respiratory System Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Antitubercular Agents Phase 2
36 Cytochrome P-450 CYP3A Inducers Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 2
38 Imatinib Mesylate Phase 2 220127-57-1 123596
39 Protein Kinase Inhibitors Phase 2
40
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
41 Pharmaceutical Solutions Phase 1
42
Mebendazole Approved, Vet_approved 31431-39-7 4030
43
Piperazine Approved, Vet_approved 110-85-0 4837
44
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
45
Suramin Approved, Investigational 145-63-1 5361
46
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
47 Piperazine citrate
48 Liver Extracts Not Applicable
49 Citrate Nutraceutical

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Twice Yearly Treatment for the Control of LF Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 4 Albendazole
6 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Recruiting NCT03052998 Phase 4 Ivermectin
7 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
8 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4 Praziquantel
9 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
10 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
11 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis Completed NCT02839772 Phase 3
12 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
13 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
14 A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Recruiting NCT02929134 Phase 3 Doxycycline;Placebo
16 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
17 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Not yet recruiting NCT02929121 Phase 3 Doxycycline;Placebo
18 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
19 Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Completed NCT00340691 Phase 2 Doxycycline
20 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00339417 Phase 2 Albendazole;Ivermectin
21 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00375583 Phase 2 DEC/Albendazole
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
25 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
26 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
27 Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Active, not recruiting NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
28 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
29 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
30 Relative Bioavailability Study of Emodepside IR-tablets and Solution Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
31 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
32 Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside Recruiting NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
33 Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Active, not recruiting NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
34 Exhaled NO Testing in Filariasis Completed NCT01628497
35 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
36 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
37 Research for Elim of Filariasis Completed NCT00145223
38 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
39 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
40 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
41 Interaction Between HIV and Lymphatic Filariasis Completed NCT00295698 Not Applicable Diethylcarbamazine
42 Medical Implications of Coinfection With Malaria and Filariasis Parasites Completed NCT00471666
43 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
44 Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area Completed NCT00139100 Not Applicable antimicrobial agent in soap
45 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis Completed NCT00344279
46 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
47 Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
48 Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 Not Applicable albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
49 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
50 Study of Patients With Strongyloides Stercoralis Infection Completed NCT00001245

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: elephantiasis, filarial

Sources

Genetic Tests for Filarial Elephantiasis

About this section
Sources

Anatomical Context for Filarial Elephantiasis

About this section

MalaCards organs/tissues related to Filarial Elephantiasis:

41
Skin, Testes, Eye, Liver, T Cells, Endothelial, Lymph Node
Sources

Publications for Filarial Elephantiasis

About this section

Articles related to Filarial Elephantiasis:

(show top 50) (show all 512)
# Title Authors Year
1
An assessment of mosquito collection techniques for xenomonitoring of anopheline-transmitted Lymphatic Filariasis in Ghana. ( 29898803 )
2018
2
Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea. ( 29224979 )
2018
3
Understanding heterogeneities in mosquito-bite exposure and infection distributions for the elimination of lymphatic filariasis. ( 29386362 )
2018
4
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
5
Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. ( 29444078 )
2018
6
Elimination of lymphatic filariasis as a public health problem from the Cook Islands. ( 29785168 )
2018
7
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. ( 29860672 )
2018
8
Elucidation of immunological response and its regulatory network by P-TUFT-ALT-2: a promising fusion protein vaccine for human lymphatic filariasis. ( 29892388 )
2018
9
Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia. ( 29801511 )
2018
10
Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. ( 29885437 )
2018
11
Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. ( 29907117 )
2018
12
Bilateral vulval filarial elephantiasis. ( 29472427 )
2018
13
Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis. ( 29916444 )
2018
14
Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. ( 29361964 )
2018
15
Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. ( 29774296 )
2018
16
Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models. ( 29860286 )
2018
17
Integrated morbidity mapping of lymphatic filariasis and podoconiosis cases in 20 co-endemic districts of Ethiopia. ( 29965963 )
2018
18
Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary? ( 29402636 )
2018
19
Island-Wide Surveillance of Gastrointestinal Protozoan Infections on Fiji by Expanding Lymphatic Filariasis Transmission Assessment Surveys as an Access Platform. ( 29405101 )
2018
20
Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. ( 29308790 )
2018
21
Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. ( 29433461 )
2018
22
Progress on elimination of lymphatic filariasis in Sierra Leone. ( 29866207 )
2018
23
Cervical Lymphatic Filariasis in a Pediatric Patient: Case Report and Database Analysis of Lymphatic Filariasis in the United States. ( 29848402 )
2018
24
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. ( 29943709 )
2018
25
Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. ( 29391042 )
2018
26
Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis. ( 28381279 )
2017
27
How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. ( 28949987 )
2017
28
Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration. ( 28794687 )
2017
29
Integrated morbidity management for lymphatic filariasis and podoconiosis, Ethiopia. ( 28867846 )
2017
30
Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a <i>Loa loa</i> co-endemic area: The Angolan experience. ( 29774284 )
2017
31
Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt. ( 28785097 )
2017
32
Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis. ( 28828575 )
2017
33
Follow-up Study of Patients Previously Diagnosed with Lymphatic Filariasis in Korea. ( 29354401 )
2017
34
Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. ( 28785847 )
2017
35
Continental-scale, data-driven predictive assessment of eliminating the vector-borne disease, lymphatic filariasis, in sub-Saharan Africa by 2020. ( 28950862 )
2017
36
Screening and evaluation of lymphatic filariasis in immigrants from endemic countries residing in a focus where it is considered eliminated in the Southern Region of Brazil: A risk of reemergence? ( 28823910 )
2017
37
Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. ( 28922418 )
2017
38
Seroprevalence of lymphatic filariasis among migrant workers in Peninsular Malaysia. ( 29206992 )
2017
39
Twelve-month longitudinal parasitological assessment of lymphatic filariasis-positive individuals: impact of a biannual treatment with ivermectin and albendazole. ( 28891597 )
2017
40
Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria. ( 28749759 )
2017
41
The National Programme to Eliminate Lymphatic Filariasis from Ethiopia. ( 28878429 )
2017
42
Generation and selection of naA^ve Fab library for parasitic antigen: Anti-BmSXP antibodies for lymphatic filariasis. ( 28833498 )
2017
43
Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria. ( 29020042 )
2017
44
Community-based field implementation scenarios of a short message service reporting tool for lymphatic filariasis case estimates in Africa and Asia. ( 28828375 )
2017
45
The Current Status of Molecular Xenomonitoring for Lymphatic Filariasis and Onchocerciasis. ( 28756911 )
2017
46
For as long as necessary: examining 30 years of Merck &amp;amp; Co., Inc.'s focus on achieving elimination of onchocerciasis and lymphatic filariasis. ( 29186497 )
2017
47
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. ( 28056015 )
2017
48
How Frank Hawking, DM, and Table Salt, Helped Eliminate Lymphatic Filariasis From China. ( 28793168 )
2017
49
Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 28303006 )
2017
50
Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 antibodies on IgE-activated granulocytes. ( 28742098 )
2017
Sources

Variations for Filarial Elephantiasis

About this section
Sources

Expression for Filarial Elephantiasis

About this section
Search GEO for disease gene expression data for Filarial Elephantiasis.
Sources

Pathways for Filarial Elephantiasis

About this section
Sources

GO Terms for Filarial Elephantiasis

About this section
Sources

Sources for Filarial Elephantiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....